FDA Inspection 1103284 — GlaxoSmithKline LLC
The FDA completed an inspection of GlaxoSmithKline LLC on Sep 12, 2019 in Durham, NC. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Sep 12, 2019
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Durham, NC (United States)
Additional details
Postmarket Adverse Drug Experience (PADE)